Gaviscon Liquid 10ml sachets

Land: Storbritannia

Språk: engelsk

Kilde: MHRA (Medicines & Healthcare Products Regulatory Agency)

Aktiv ingrediens:

Sodium alginate; Sodium bicarbonate; Calcium carbonate

Tilgjengelig fra:

Reckitt Benckiser Healthcare (UK) Ltd

ATC-kode:

A02BX

INN (International Name):

Sodium alginate; Sodium bicarbonate; Calcium carbonate

Dosering :

50mg/1ml ; 26.7mg/1ml ; 16mg/1ml

Legemiddelform:

Oral suspension

Administreringsrute:

Oral

Klasse:

No Controlled Drug Status

Resept typen:

Never Valid To Prescribe As A VMP

Produkt oppsummering:

BNF: 01010201; GTIN: 5000158066601

Preparatomtale

OBJECT 1
GAVISCON LIQUID SACHETS MINT FLAVOUR
Summary of Product Characteristics Updated 21-Nov-2014 | Reckitt
Benckiser Healthcare (UK) Ltd
1. Name of the medicinal product
Gaviscon Liquid Sachets Mint Flavour
2. Qualitative and quantitative composition
Gaviscon contains 500 mg sodium alginate, 267 mg sodium bicarbonate
and 160 mg calcium carbonate
per 10 ml dose.
Excipients: methyl parahydroxybenzoate (E218) 40 mg/10 ml and propyl
parahydroxybenzoate (E216) 6
mg/10 ml.
For a full list of excipients, see Section 6.1.
3. Pharmaceutical form
Oral suspension in sachets.
An off-white suspension with the odour and flavour of peppermint.
4. Clinical particulars
4.1 Therapeutic indications
Treatment of symptoms of gastro-oesophageal reflux such as acid
regurgitation, heartburn and indigestion
related to reflux, for example, following meals, or during pregnancy,
or in patients with symptoms related
to reflux oesophagitis.
4.2 Posology and method of administration
For oral administration.
Adults and children 12 years and over: One to two sachets after meals
and at bedtime (up to four times a
day).
Children under 12 years: Should be given only on medical advice.
Elderly: No dose modifications necessary for this age group.
4.3 Contraindications
This medicinal product is contraindicated in patients with known or
suspected hypersensitivity to the
active substances or to any of the excipients listed in section 6.1,
including methyl parahydroxybenzoate
(E218) and propyl parahydroxybenzoate (E216) (see section 4.4).
4.4 Special warnings and precautions for use
If symptoms do not improve after seven days, the clinical situation
should be reviewed.
Sodium content of a 10 ml, one sachet dose is 141 mg (6.2 mmol). This
should be taken into account
when a highly restricted salt diet is required, e.g. in some cases of
congestive cardiac failure and renal
impairment.
Each 10 ml, one sachet dose contains 160 mg (1.6 mmol) of calcium
carbonate. Care needs to be taken in
treating patients with hypercalcaemia, nephrocalcinosis and recurre